Does Earnings Surprise History Hold Any Clue for Zimmer Biomet (NYSE:ZBH)

Earnings results for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. is expected* to report earnings on 05/04/2021 before market open. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 14 analysts’ forecasts, the consensus EPS forecast for the quarter is $1.51. The reported EPS for the same quarter last year was $1.7.

Zimmer Biomet last posted its quarterly earnings results on February 4th, 2021. The medical equipment provider reported $2.11 EPS for the quarter, topping analysts’ consensus estimates of $2.06 by $0.05. The firm earned $2.09 billion during the quarter, compared to analysts’ expectations of $2.08 billion. Its quarterly revenue was down 1.9% compared to the same quarter last year. Zimmer Biomet has generated $7.87 earnings per share over the last year and currently has a price-to-earnings ratio of 1,107.3. Zimmer Biomet has confirmed that its next quarterly earnings report will be published on Tuesday, May 4th, 2021. Zimmer Biomet will be holding an earnings conference call on Tuesday, May 4th. Interested parties can register for or listen to the call using this link.

Analyst Opinion on Zimmer Biomet (NYSE:ZBH)

22 Wall Street analysts have issued ratings and price targets for Zimmer Biomet in the last 12 months. Their average twelve-month price target is $167.86, predicting that the stock has a possible downside of 5.25%. The high price target for ZBH is $200.00 and the low price target for ZBH is $106.00. There are currently 1 sell rating, 2 hold ratings, 16 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus rating of “Buy.”

Zimmer Biomet has received a consensus rating of Buy. The company’s average rating score is 2.95, and is based on 16 buy ratings, 2 hold ratings, and 1 sell rating. According to analysts’ consensus price target of $167.86, Zimmer Biomet has a forecasted downside of 5.2% from its current price of $177.16. Zimmer Biomet has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Dividend Strength: Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet has a dividend yield of 0.54%, which is in the bottom 25% of all stocks that pay dividends. Zimmer Biomet has only been increasing its dividend for 1 years. The dividend payout ratio of Zimmer Biomet is 12.20%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Zimmer Biomet will have a dividend payout ratio of 12.15% next year. This indicates that Zimmer Biomet will be able to sustain or increase its dividend.

Insiders buying/selling: Zimmer Biomet (NYSE:ZBH)

In the past three months, Zimmer Biomet insiders have not sold or bought any company stock. Only 0.44% of the stock of Zimmer Biomet is held by insiders. 87.17% of the stock of Zimmer Biomet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Zimmer Biomet (NYSE:ZBH

Earnings for Zimmer Biomet are expected to grow by 64.58% in the coming year, from $4.80 to $7.90 per share. The P/E ratio of Zimmer Biomet is 1,107.32, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.08. The P/E ratio of Zimmer Biomet is 1,107.32, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 44.52. Zimmer Biomet has a PEG Ratio of 4.32. PEG Ratios above 1 indicate that a company could be overvalued. Zimmer Biomet has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here